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Crystallization of multi-component crystals is widely used in pharmaceutical science 
to enhance the physiochemical properties, such as stability, mechanical properties and 
solubility. Loratadine (Lor) is a BCS II antihistamine drug commonly used to relieve 
the symptoms of allergy. It has high permeability but low solubility at physiological 
pHs. To overcome the problem of low solubility, we synthesized and fully 
characterized two Loratadine multi-component crystalline phases with oxalic acid 
(Oxa), i.e., a 1:1 Lor-Oxa conjugate acid-base cocrystal (Lor-Oxa CAB) and a 2:1 Lor-
Oxa cocrystal monohydrate (Lor-Oxa hydrate).  Both cocrystals exhibited adequate 
physical stability, enhanced solubility and, higher intrinsic dissolution rate than Lor.  
The intrinsic dissolution rate of Lor-Oxa CAB is 90 times that of Lor, which makes it 
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1.1  General Introduction 
The pharmaceutical sciences is central for converting an active pharmaceutical 
ingredient (API) into a drug product. 1  The long journey of drug development starts 
from the discovery of a new chemical entity, which is followed by, among others, 
sophisticated preformulation and formulation development efforts before it becomes a 
product. Traditionally, product development is more like an art than a science. 
Formulations are developed by the trial-and-error approach based on personal 
experience and redundant data collection, which leads to low efficiency. The quality-
by-design (QbD) initiative by FDA stresses the need for more scientific formulation 
development and scale up.2 The ultimate goal of developing new drug products for 
therapeutic performance and benefits requires certain unique properties of the products, 
which are determined by materials structure. Therefore, understanding structure-
property relationship is critical to drug development. Materials Science Tetrahedron 
(MST) is a conceptual framework that depicts the interdependent relationship among 
the structure, properties, performance, and processing of a drug.3 
The successful development of a drug must overcome challenges presented by poor 
solid-state properties, 4 such as low solubility and poor dissolution performance.5 
Loratadine (Lor) is a drug that faces this problem. Lor is is a second-generation 
tricyclic H1 antihistamine, used to treat itching, congestion, rhinorrhea, tearing and 
sneezing by preventing and suppressing the response to histamine or allergen. It is non-





barrier.6 In 2002, Lor was approved for the over the counter (OTC) status by FDA. 7  
Due to its affordable cost and effectiveness, Lor has become the most widely 
administered antihistamine drug worldwide. 
Modifying the solid-state of drug molecules to improve the physical properties of an 
API is common in drug development because it does not alter pharmacological 
performances of the molecule upon dissolution.8 Therefore, the search for new solid 
forms is valuable part of drug development for developing better medicines.9 Among 
all the strategies, the powerful and versatile crystal engineering approach is common 
adopted to improve API’s physical and chemical properties.10 
The main object of this thesis research is to improve the solubility and dissolution of 
Lor through identifying suitable solid-state forms enabled by crystal engineering. In 
this study, we synthesized and characterized two Loratadine multicomponent crystals 
with oxalic acid, a 1:1 Loratadine-oxalic acid conjugate acid-base cocrystal (Lor-Oxa 
CAB) and a 2:1 Loratadine-oxalic acid cocrystal monohydrate (Lor-Oxa hydrate). 
Both crystals exhibited adequate physical stability, enhanced solubility and intrinsic 
dissolution rate.  The more than 90 fold higher intrinsic dissolution rate of Lor-Oxa 
CAB makes it a promising candidate for further formulation development.  
1.2 Solubility and Dissolution Rate 
Solubility and dissolution rate are pharmaceutical properties critical for achieving 





the substance that is in equilibrium with the solvent phase under a given environment 
condition. 11  It is a thermodynamic property corresponding to the state of phase 
equilibration between the solid phase and solution.  Solubility of a drug depends on 
temperature, pressure (of the drug or solvent is a gas), the solute-solvent intermolecular 
interactions and the polymorphic form of the solid. 12 A supersaturated solution can 
exist where the solute concentration is above the solubility but will eventually revert 
to the equilibrium. Poor solubility of drug candidates is a key challenge to 
pharmaceutical development.13 Practically, a kinetically controlled meta-stable 
solubility that is higher than the global thermodynamic solubility may be attained.  
This is the basis for the common approach of using metastable solid forms to improve 
the delivery of poorly soluble drugs.  The experimentally measured solubility of a 
poorly soluble drug is sometime underestimated due to the prolonged time period 
required to establish equilibrium resulting from a slow dissolution rate.14 Dissolution 
rate is the rate of individual solute molecules transfer from the solid particles into 
dissolution media as a free molecule.15  Many dissolution models have been 
developed, among all these models, the diffusion layer model is the most pertaining to 
the dissolution of neat API. In this model, the diffusion generates a concentration 
gradient between solute surface and the bulk media, which is called diffusion layer. 






(𝐶𝑠 − 𝐶𝑏)                                             Eq.1-1  





area of solute particle, D is the diffusion coefficient of the solute in the solvent, h is 
the thickness of the diffusion layer, Cs is the saturation concentration and Cb is the 
concentration of the solute in bulk media. From equation 1.1, it can be seen that 
solubility is a driving force for dissolution rate. When Cb<< Cs, the dissolution rate is 
proportional to solubility.17 For drugs delivered orally, they are normally first dissolved 
in gastrointestinal fluids before being absorbed. Therefore, the rate of absorption a 
lipophilic drug is usually limited by the dissolution rate because its dissolved 
molecules can permeate the membrane quickly.18 The intrinsic dissolution rate (IDR) 
is the dissolution rate of a solute normalized by surface area. It can be measured by the 
rotating disk method.19 IDR is a kinetic phenomenon rather than an equilibrium 
phenomenon, so it is affected by several experimental parameters, such as rotation 
speed. 20 
The Biopharmaceutics Classification System (BCS) II drugs have low solubility and 
high permeability, composing 60%-70% of drug molecules under development.21  As 
low solubility is a limiting factor for the bioavailability of these drugs, several 
strategies have been developed to improve their solubility, such as cosolvents, 
surfactants, crystal engineering, amorphous solid dispersions, cyclodextrins, solid 
lipid nanoparticles, and other colloidal drug delivery systems22 
1.3 Tablets and Tablet Strength   
The tablet dosage form usually contains API and suitable pharmaceutical excipients 





pharmaceutical dosage form that account for more than 80% of all dosage forms 
administered to humans.24 25 The popularity of tablets can be attributed to their 
advantages in both manufacturing and administration, including accurate dose, 
stability, easy to handle and storage, lower manufacturing cost than other dosage forms, 
and possibility for high volume production.26 For the patients, the tablets are easy to 
administer and may be divided into halves or quarters when a fractional dose is 
required. 24 Specially designed tablets with modified-release or specific route of 
administration are also possible.27 For Lor, swallowable, chewable, and orally 
disintegrating tablets have been marketed. 
A good tablet product should meet the criteria of stability, content uniformity, 
manufacturability, bioavailability, bioequivalency (for a generic product), 
pharmaceutical elegance, and low cost if possible. 28 Adequate mechanical strength is 
required for a tablet to survive downstream processing, handling and shipping, 
averting unacceptable loss of drug content, 29-30 but excessive strength could lead to 
longer distinguish time and slower drug release or make the tablets too hard to break. 
5 Solid state properties (e.g., hygroscopicity, solid form, crystal structure), mechanical 
properties (e.g., plasticity, elasticity, brittleness) and powder properties (e.g., particle 
size and shape, surface energy) can all influence the tableting behavior of APIs.31 
Therefore, the first step of tablet design or formulation development is to have a full 
understanding of the physicochemical properties of the API.  





compaction pressure, tensile strength (TS), and solid fraction (porosity) (Figure 1.1),  
which are critical to understand the compaction behavior.32 Tensile strength can be 
understood based on the qualitative bonding area (BA)-bonding strength (BS) model, 
where contributions of BA and BS are simultaneously considered.5 BS accounts for 
intermolecular interactions, mainly including van der Waals and hydrogen bonds for 
molecular solids. During the consolidation of a powder, particles undergo permanent 
deformation to result in BA. Hence, BA depends on compaction conditions, 
mechanical properties (plastic, elastic), and particle properties (e.g., size, shape). BA 
and BS can be assessed by compressibility and compactibility, respectively. Both 
larger BA and BS favor higher TS.  
1.4 Crystal Engineering 
The concept “crystal engineering” was first mentioned in 1955, 33 and officially 
appeared in the literature in 1971 when Gerhard Schmidt listed ”crystal engineering” 
as one of the four concurrent and connected phases of solid-state photochemical 
research.34 Crystal engineering may be defined as “The understanding of 
intermolecular interactions in the context of crystal packing and the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties”10. The intermolecular interactions formed the smallest structural units, 
supramolecular synthons, through which molecules assemble into supramolecules. 35 
There are four steps in crystal engineering: observation of structural groups, 





predictions35 With the unremitting invention of the crystallographic techniques, crystal 
engineering went over a rapid development. Today, it is widely used in multi fields 
including chemistry, material science and pharmaceutical science.  
In pharmaceutical sciences, crystal engineering is utilized to obtain desirable 
mechanical and physicochemical properties of drug compounds without altering their 
pharmacological performances 36 through the methods of habit modification, surface 
modification, polymorphism, solvation formation, and cocrystalization.37 Among all 
the techniques, cocrystallization has been widely used to improve the physicochemical 
properties of pharmaceutical compounds, including physical stability (sublimation 
tendency, and hydration tendency)38-39, chemical stability, solubility40 and 
dissolution41, mechanical properties29, permeability42, and punch sticking propensity.43 
Such multi-component crystals exploit noncovalent interactions between neutral 
molecular or ionic components with a well-defined stoichiometry in a solid-state 
structure44. Hydrogen bonding is one of the most important interactions for designing 
a cocrystal.   Etter proposed the following Hydrogen-Bond Rules based on the 
examination of functional groups and hydrogen-bond patterns in a vast number of 
crystals 45: “1. All good proton donors and acceptors are used in hydrogen bonding. 
2. Six-membered ring intramolecular hydrogen bonds form in preference to 
intermolecular hydrogen bonds. 3. The best proton donor and acceptor remaining 
after intramolecular hydrogen-bond formation will form intermolecular hydrogen 
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Loratadine (Lor) is a BCS II antihistamine drug commonly used to relieve the 
symptoms of allergy. It has high permeability but low solubility at physiological pHs. 
In this study, we synthesized two Lor multicomponent crystals with oxalic acid (Oxa), 
i.e., 1:1 Lor-Oxa conjugate acid-base cocrystal (Lor-Oxa CAB) and 2:1 Lor-Oxa 
cocrystal monohydrate (Lor-Oxa hydrate). Both Lor-Oxa crystals exhibited adequate 
physical stability, enhanced solubility and intrinsic dissolution rate (IDR).  Overall 
results suggest that Lor-Oxa CAB is a promising candidate for further tablet 














2.1 Introduction    
Low aqueous solubility is a major challenge to the design of oral solid forms.46 It may 
lead to poor drug bioavailability because of the slow dissolution process before drug 
molecules can be absorbed into the systemic circulation. Many approaches have been 
developed to enhance solubility or dissolution, including particle size reduction, 
cosolvents, surfactants, more soluble crystal forms, amorphous solid dispersions, 
cyclodextrins, solid lipid nanoparticles, and other colloidal drug delivery systems.22 
Cocrystallization is a crystal engineering technique widely used in pharmaceutical 
research and development of drugs.44, 47 It exploits noncovalent interactions between 
neutral or ionic components with a well-defined stoichiometry in a solid-state 
structure,9 which could improve the physicochemical properties of active 
pharmaceutical ingredients (API), including physical stability (sublimation tendency, 
and hydration tendency)38-39, solubility40 and dissolution41, mechanical properties29, 
permeability42 , and punch sticking propensity.43, 48 
Loratadine (Lor) (Figure 2.1.a) is a second-generation tricyclic H1 antihistamine, used 
to treat itching, congestion, rhinorrhea, tearing and sneezing by preventing and 
suppressing the response to histamine or allergen. Its non-sedating nature, due to the 
high peripheral selectivity and low ability to cross the blood-brain barrier, makes it a 
medicine of choice for treating allergies.6 Lor is a weakly basic drug (pKa = 5.25),49 
belonging to the Biopharmaceutical Classification System (BCS) Class II.50 The 





high variability in pharmacokinetic parameters. 50-51  The solubilty of Lor in pH 6/8 
phosphate buffer is 0.7 mg/L.52  Given the wide use of Lor, a new crystal form of Lor 
with improved solubility and dissolution rate, which reduceds variability in 
bioavailability, as well as enhanced powder properties for more efficient 
pharmaceutical processing is desired for developing new Lor tablets with better in vivo 
performance.53  Past efforts to improve the solubility of Lor include the use of 
complexes 54-55, solid dispersion56-57, solid lipid microparticles58, solid lipid 
nanoparticles59, self microemulsifying particles,60 and coamorphous systems.61 
However, the cocrystal/salt approach has been so far unsuccessful.62 
In this study, a series of organic acids, as potential coformers or salt former, were 
screened. Two new multicomponent crystalline forms of Lor (Figure 2.1.b) were 
discovered, i.e., a Lor - Oxalic acid (Oxa) conjugate acid-base salt (Lor-Oxa CAB) 
with the Lor to Oxa ratio of 1: 1 and Lor-Oxa cocrystal monohydrate (Lor-Oxa hydrate, 
Lor:Oxa = 2:1).  The pharmaceutical properties, including crystal structure, 
dissolution, thermal property, physical stability and mechanical property, of both new 
crystal forms were characterized for suitability to develop a tablet product with a faster 
and more robust drug release performance and manufacturability. Both new cocrystals 
exhibited enhanced solubility and intrinsic dissolution rate (IDR).  However, ~95 fold 






2.2 Materials and Methods  
2.2.1 Materials 
Loratadine was purchased from; Wuhan Biocar Bio-pharm Co. Ltd. (Wuhan, Hubei, 
China). Oxalic acid, resorcinol, malonic acid, benzoic acid, DL-malic acid, nicotinic 
acid, and succinic acid were all purchased from Sigma−Aldrich (St. Louis, MO) and 
were used as received. Microcrystalline cellulose (MCC; Pharmacel 102) was 
provided by DFE Pharma (Goch, Germany).  
2.2.2 Screen for Loratadine Salt/Cocrystals 
Each candidate carboxylic acid was suspended with Lor, in 1:1 molar ratio, in various 
solvents, including ethanol, ethyl acetate, isopropanol, methanol, and acetone. 1 mmol 
of each of Lor and a carboxylic acid powders were fully dissolved in 5 mL of a solvent 
in a vial with heating. The vial was then left open in a fume hood to allow solvent to 
evaporate.  The resulting solid was characterized by powder X-ray diffraction (PXRD) 
to identify possible new crystal form.  
2.2.3 Single Crystal Preparation 
Equimolar Lor (765.76 mg, 2 mmol) and Oxa (180.08 mg, 2 mmol) or 2:1 molar ratio 
Lor (765.76 mg, 2 mmol) and Oxa (90.04 mg, 1 mmol) were dissolved in 6 mL of 
acetone. The vials were left in a cold room (4oC), covered by parafilm with holes 
introduced to allow slow evaporation of the solvent and crystal growth. Crystals 





Oxa CAB and Lor-Oxa hydrate were obtained form 1:1 and 2:1 samples, respectively.  
2.2.4 Single Crystal X-Ray Diffractometry (SCXD) 
A Bruker-AXS Venture Photon-II diffractometer (Bruker AXS Inc., Madison, 
Wisconsin), with a Photon-II (CMOS) detector, was used to collect the SCXRD data 
at 100 K using Mo Kα radiation (graphite monochromator).  A suit of software, 
including APEX3, SADABS and SAINT, was used for data analysis.  The structures 
were solved using SHELXT 2014 program and refined using SHELXL 2018 program. 
Based on systematic absences and intensity statistics, the space group P21/c was 
determined. A direct-methods solution was calculated, which provided most non-
hydrogen atoms from the E-map. Full-matrix least-squares/difference Fourier cycles 
were performed to locate the remaining non-hydrogen atoms. All non-hydrogen atoms 
were refined with anisotropic displacement parameters. All hydrogen atoms were 
placed in ideal positions and refined as riding atoms with isotropic displacement 
parameters. 
2.2.5 Bulk Powder Preparation   
Bulk powder of Lor-Oxa CAB was prepared by completely dissolving 4.59 g of Lor 
(12 mmol) and 1.08 g of Oxa (12 mmol) in 15 mL of acetone at room tempeature. The 
slution was placed in a cold room (4 oC) with continuous stirring for 24 h. The 
precipitant was then washed with acetone, filtered, and dried in a 35 oC oven for 
overnight.  A bulk powder of Lor-Oxa hydrate was prepared in a similar way, except 





and slightly heated to obtain a clear solution before the sample was placed in the cold 
room.  
2.2.6 Powder X-ray Diffractometry (PXRD) 
Powder X-ray diffractograms were collected using a powder X-ray diffractometer 
(X’pert Pro; PANalytical, Westborough, MA) equipped with Cu Kα radiation (1.54059 
Å). Samples were scanned between 5 to 30° 2θ with a 0.02° step size and a 1 s/step 
dwell time at ambient temperature. The tube voltage and amperage were set at 45 kV 
and 40 mA, respectively. 
2.2.7 Thermal Analysis 
The thermal properties of powders were characterized by thermogravimetric analysis 
(TGA) and differential scanning calorimetry (DSC). 
DSC data was collected using a thermogravimetry analyzer (Model Q500, TA 
Instruments, New Castle, DE, USA). Powder samples (approximately 3 mg) were 
heated in open aluminum pans from room temperature to 300 °C at 10 °C/min under 
60 mL/min dry nitrogen purge. 
DSC data was collected on a differential scanning calorimeter (Q1000, TA Instruments, 
New Castle, DE, USA). Powder samples (~3 mg) were loaded into hermetically sealed 
aluminum Tzero pans and heated with a heating rate of 10 °C/min from room 





To assess the stability of Lor-Oxa hydrate, a powder sample was placed in a 100 oC 
oven.  An aliquot of powder was taken out for PXRD analysis after 1, 2, 3, 4, 5, 6, 
12, and 18 days. 
2.2.8 Hot Stage Microscopy (HSM) 
HSM was performed with a polarized light microscopy (Eclipse e200; Nikon, Tokyo, 
Japan). Images of crystals were captured by a DS Fi1 microscope digital camera. 
Crystals were heated to 150 oC at the rate of 5 °C/min with a temperature controller 
(Linksys 32; V.2.2.0, Linkam Scientific Instruments, Ltd., Waterfield, UK). 
2.2.9 Fourier Transformation Infrared Spectroscopy  
(FT IR) 
FT-IR spectra (in the range of 4000−400 cm−1) of dry powders were obtained using a 
FT-IR spectrometer (NicoletiS50; Thermo Scientific, Waltham, MA) equipped with a 
diamond attenuated total reflection (ATR) and DLaTGS detector. The spectrum of each 
sample was an average of 32 scans with a spectral resolution of 2 cm−1. Data 
processing was performed with the OMNIC 9.2 software. 
2.2.10 Moisture Sorption and Desorption 
Isothermal water sorption and desorption isotherms were collected using an automated 
vapor sorption analyzer (Intrinsic DVS, Surface Measurement Systems Ltd., 
Allentown, PA, USA) at 25°C with nitrogen flow rate of 50 mL/min. Sample weight 





dry nitrogen until a constant weight was obtained. The RH was varied from 0% to 95% 
during sorption followed by 95% to 0% during desorption with a step size of 5% RH. 
For Lor-oxa hydrate, the powder sample was exposed to a series of relative humidities 
(RH) from 95 % to 0% then back to 95% with a step size of 5% RH. Samples were 
equilibrated at each step with the equilibration criteria of either dm/dt = 0.003% or 
maximum equilibration time of 6 h was reached before changing to the next target RH. 
2.2.11 Solubility and Intrinsic Dissolution Rate (IDR)  
Solubility was determined by suspending an excess amount of a solid (100 mg) in 5 
mL of pH 6.8 phosphate buffer under stirring at 25 °C for 72 h. Each suspension was 
passed through a 0.45 μm PTEE membrane filter. The filtrate was appropriately diluted 
with the medium for measurement by a UV−vis fiber optic probe (Ocean Optics, 
Dunedin, FL) at 250 nm.  Solution concentration was calculated based on a 
previously constructed calibration curve (Figure 2.2). The residual solids were 
collected and tested by PXRD to verify the solid phase.  
The IDR was determined by the rotating disc method63 64 in a phosphate buffer at pH 
6.8 to mimic duodenum pH. For each sample, approximately 20 mg of powder was 
compressed at a force of 2000 lb, using a custom-made stainless-steel die, against a 
flat stainless-steel disc for 2 min to prepare a pellet (6.39 mm in diameter). The surface 
of the pellet was visually smooth and coplanar with the die surface. While rotating at 
200 rpm, the die was immersed in a 200 mL dissolution medium at 37°C in a water-





to continuously monitor the UV absorbance of the solution at λ = 250 nm. IDR was 
calculated from the slope of the linear portion of the concentration time profile and the 
pellet surface area exposed to the dissolution medium. PXRD of the pellet after IDR 
was collected to either confirm or eliminate the possibility of phase transition during 
dissolution. 
2.2.12 Tabletability  
Powder compaction was carried out using a universal material testing machine (model 
1485; Zwick/ Roell, Ulm, Germany). To minimize the effect of particle size, powder 
samples were ground in a mortar with a pestle and passed through a # 60 mesh (≤ 250 
μm) sieve before compaction. Particle sizes were assessed by polarized light 
microscopy. Three mixtures conatining 25% (w/w) of one of the three Lor crystal 
forms and 75% (w/w) of MCC PH102, were blended using a Turbula mixer (Glen 
Mills Inc., Clifton, NJ) for 5 min at 49 rpm. Tablets were compacted under pressures 
ranging from 25 to 350 MPa at a speed of 4 mm/min, using flat faced round punches 
(8 mm diameter). For pure crystal forms, the punch tip and die wall were lubricated 
with a suspension of magnesium stearate in ethanol (5% w/v) and air dried prior to 
each compaction. For mixtures with MCC, no lubricant was used because the low 
tendency of punch sticking and low ejection force. Tablets were relaxed for at least 24 
h in a tightly closed glass vial before their dimensions were measured and broken 
diametrically with a texture analyzer (TA-XT2i; Texture Technologies Corporation, 








                                                          (2-1) 
Where F is the breaking force, D is tablet diameter, and h is tablet thickness. 
Powder true density was measured using a helium pycnometer (Quantachrome 
Instruments, Ultrapycnometer 1000e, Byonton Beach, Florida). Approximately 1 g of 
each powder was accurately weighed and placed into a sample cell (10 mL cell 
volume). The measurement was stopped when the coefficient of variation of the last 
five consecutive volume measurements was less than 0.005% or after 100 
measurements, in which case the last five measurements were used to calculate an 




                                                          (2-2) 
where ρ and ρt are tablet density and powder true density, respectively. 
2.3 Results and Discussion 
2.3.1 Crystal Screening and Structure Analysis 
Slurrying Lor and Oxa at 2:1 and 1:1 molar ratios led to two PXRD patterns different 
from those of the starting Lor and Oxa, suggesting that new solid forms were obtained 
(Figure 2.3).  
Single crystal structures solved by SCXRD confirmed they are new crystalline 





the crystal belongs to the P21/c space group of the monoclinic system.  Its unit cell 
consisted of six asymmetric units (Z=6). The asymmetric unit is consisted of cationic 
Lor+, anionic Oxa-, and neutral Oxa at the molar ratio of 2:1:1 (Figure 2.4 a). Key 
crystallographic information is summarized in Table 2.1. In this structure, 1D Oxa 
chains running along the b axis were formed via hydrogen bonds of O-H∙∙∙O- (2.510, 
2.512, 2.515 Å)（Figure 2.4b).  The Oxa chains are connected with Lor+ through N+-
H∙∙∙O=C (2.624, 2.726 Å) and N+-H∙∙∙O- (2.897, 2.988 Å) (Figure 2.4c). The adjacent 
chains formed a 2D layer structure through π∙∙∙π (3.439 Å), Cl∙∙∙π (3.320 Å) stacking, 
and C=O∙∙∙H-C (3.402 Å) hydrogen bond along the (-1 0 -2) plane.  The adjacent 
layers stack to form a 3D packing structure, stabilized by weak C-H∙∙∙O (3.520 Å) 
hydrogen bonds (Figure 2.4d). 
When crystallized from the 2:1 Lor:Oxa solution, the crystalline phase also belongs to 
the monoclinic P21/c space group.  Its unit cell contains 4 asymmetric units (Z=4), 
each comprised of 1 Lor, 0.5 Oxa (Oxa has an axis of symmetry), and one water 
molecue (Figure 2.5 a). Key crystallographic information is summarized in Table 2.1. 
Lor and water interact via C=O… H-O (2.977 Å) and O-H…Cl (3.232 Å) hydrogen 
bonds to form 1D chains(Figure 2.5 b). One Oxa molecule further connects to two Lor 
molecules in adjcent chains via O-H∙∙∙N (2.609 Å), C-H∙∙∙O=C (3.322 Å), C∙∙H-O 
(3.448 Å, 3.528 Å) hydrogen bonds (Figure 2.5 c) to form 2D zig-zaged layers. Finally, 
the layers stack to form a 3D packing structure. (Figure 2.5 d)   





PXRD patterns of the solids obtained from the slurry method (Figure 2.3).  
2.3.2 Formation Conditions of the Two Crystals 
Given that Lor-Oxa CAB could be obtained at 1:1 Lor to Oxa ratio, and Lor-Oxa 
hydrate was prepared at 2:1 ratio. The amount of Oxa is expected to play a key role in 
phase stability of both crystals.  Slurry experiments at different Lor to Oxa ratios 
suggested that Lor to Oxa ratio did affect solid form, as shown by the PXRD patterns 
(Figure 2.6).  Phase change was monitored using unique peaks of Lor at 7.52 degree 
two-theta (marked with a yellow dashed line), Lor-Oxa CAB at 10.04 degree two-theta 
(marked with a blue dashed line) and 19.93 degree two-theta (marked with green 
dashed line), Lor-Oxa hydrate at 8.87 degree two-theta (marked with a black dashed 
line). At ratio 1:0.2, the product is a mixture of Lor and Lor-Oxa hydrate. For 1:0.3 to 
1:0.5 ratios, pure Lor-Oxa hydrate was obatined.  At 1:0.6 to 1:0.9 ratios, the powders 
are mixtures of Lor-Oxa hydrate and Lor-Oxa CAB, where the amount of Lor-Oxa 
CAB increases with increasing Oxa amount. When the Lor to Oxa ratio reaches 1:1, 
the product is pure Lor-Oxa CAB form.  
2.3.3 Solid State Characterization 
Differential scanning calorimetric (DSC) thermograms of Lor-Oxa CAB exhibited a 
single endotherm with an onset temperature of 124.29 °C (ΔHf = 69.78 J/g) and peak 
temperature of 129.72o (Figure 2.7 a). The TGA profile (Figure 2.7 b) showed 
negligible weight loss below 150 oC, suggesting acceptable thermal stability.  This is 





weight loss was observed at ≥ 150 oC, likely due to the evaporation of Oxa from the 
melt.  A Lor-Oxa CAB single crystal melted at 135 oC in a HSM study (Figure 2.7 c), 
the higher melting point by HSM than that by DSC is attributed to the thermal lag 
during the HSM experiment.  
The weight loss of Lor-Oxa hydrate corresponds to dehydration, which initiated at 
around 92 oC and proceeds slowly until the accelerated weight loss at ≥112 oC (Figure 
2.7 b). The DSC thermogram of Lor-Oxa hydrate exhibited two overlapping 
endotherms with onset temperature of 119.84 °C (ΔH f = 93.88 J/g) (Figure 2.7a).  
The onset temperature of the DSC endotherm is ~28 oC higher than the temperature 
corresponding to the initial weight loss observed on TGA.  This temperature 
difference is larger than expected, which may partially result from the depression of 
the dehydration reaction by the build up of water vapor from the initial dehydration in 
DSC pan.  A Lor-Oxa single crystal released water bubbles when heated to 101 oC 
and continued through the melting of the crystal in the temperature range of 130 - 136 
oC (Figure 2.7 d).  This is consistent with the significant overlap of the two 
endotherms observed in the DSC thermogram of Lor-Oxa (Figure 2.7a).  
The FT-IR spectra of Lor, Oxa, and two Lor cocrystals show distinct peaks (Figure 
2.8).  The strongest sharp absorption band at 1698 cm-1 of the Lor is attributed to the 
C=O of the ester group, which is distinct from the broad C=O absorption bands of the 
two carboxylic acid groups with a peak position at 1668 cm-1. The larger red-shift of 





explained by the O-H∙∙∙O (2.977 Å) hydrogen bond formation between ester C=O and 
water. The ≥100 cm-1 red-shift of the C=O absorption band of a fully deprotonated 
carboxylate group 67 was not obvious in the FTIR spectra of both Lor-Oxa hydrate and 
Lor-Oxa CAB because of the overlapping of the much stronger C=O absorption bands 
of Lor. The low intensity of O-H absorption bands of Oxa in Lor-Oxa CAB is attributed 
to its participation in strong charge assisted hydrogen bonds of O-H∙∙∙O- (2.510, 2.512, 
2.515 Å) and absence of water. In contrast, the hydroxyl groups of water and Oxa in 
Lor-Oxa hydrate only participate in weak hydrogen bonds (O-H∙∙∙O, 2.977 Å; O-H∙∙∙Cl, 
3.232 Å).    
2.3.4 Moisture Sorption and Desorption Behavior.  
Both Lor-Oxa CAB and Lor-Oxa hydrate gained less than 1% weight up to 95% RH 
and only slight hysterisis between sorption and desorption curves was observed 
(Figure 2.9). Therefore, the weight change of both samples is due to the surface 
adsorption not hydration/dehydration.  The physical stability of Lor-Oxa hydrate 
against changes in RH is consistent with the thermal data (Figure 2.7), which suggests 
that dehydration did not occur under dry nitrogen purge until temperature was at least 
92 oC.   When stored at a 100 oC oven, Lor-Oxa hydrate did not undergo detectable 
dehydration after 1 day base on PXRD (Figure 2.10).  Characteristic peaks of Lor, 
e.g., 12.7 o two theta, appeared after two days.  However, an appreciable amount of 
Lor-Oxa hydrate remained even after 6 days.  Complete conversion to Lor was 





stabilization of water in the crystal structure by forming C=O…H-O (2.977 Å) and O-
H…Cl (3.232 Å) hydrogen bonds.  Therefore, Lor-Oxa hydrate could be used in 
typical pharmaceutical manufacturing and storage conditions without a high risk of 
phase change. 
2.3.5 Solubility and Intrinsic Dissolution Rate 
Both solubilities and dissolution rates of the two new crystal forms of Lor are 
determined in pH 6.8 phosphate buffer to mimic the human physiology environment. 
During solubility measurement at 25 oC, Lor-Oxa CAB converted to Lor-Oxa hydrate 
within three days while Lor-Oxa hydrate remained stable. The phase change suggests 
that Lor-Oxa CAB is more soluble than Lor-Oxa hydrate in the pH 6.8 buffer.68  
Compared to Lor, Lor-Oxa hydrate displays both improved solubility (1.46× ) and 
intrinsic dissolution rate (1.85×) (Figure 2.12 a.b, Table 2.2).  Lor-Oxa CAB exhibits 
a much higher IDR, about 95 times of Lor. In the IDR curve of Lor-Oxa CAB, the 
concentration of Lor in the medium initially increased linearly up to a concentration 
of 11.36 ±0.37 μg/mL and then decreased (Figure 2.14). The PXRD pattern of the Lor-
Oxa CAB pellet after IDR experiment matched that of Lor-Oxa hydrate, indicating 
conversion to Lor-Oxa hydrate (Figure 2.12 c). The decline in the concentration of Lor 
beyond 10 min suggests bulk precipitation, which explains the observed turbidity of 
the dissolution medium (Figure 2.12 d). Since the degree of supersaturation is the 
highest at the surface of pellet, free drug tends to precipitate out more easily at the 





study the bulk precipitation phenomenon. Potential reasons for bulk precipitation 
include: (a) The high dissolution rate leads to faster receding of the pellet surface than 
the time required to form nuclei in absence of a solid surface; and (b) the pH in the 
diffusion layer is lower than that in the bulk medium, which leads to a lower degree of 
supersaturation of Lor since the solubility of Lor is higher at a lower pH. 
2.3.6 Tabletability 
Tabletability is an important property of drugs for successful tablet formulation, 
especially when the drug loading is high.69 Both new Lor crystal forms exhibited 
reduced tabletbility than Lor over the entire compaction pressure range of 25 – 350 
MPa (Figure 2.15 a). The tablet tensile strength of Lor-Oxa CAB increased with 
increasing pressure up to 200 MPa, beyond which higher pressure led to slightly lower 
tensile strength.  Similar observation occurs for the Lor-Oxa hydrate, although the 
decline in tensile strength occurred at pressures higher than 100 MPa. At 350 MPa, 
intact tablets of Lor-Oxa hydrate could not be made due to extensive lamination of 
tablets (Figure 2.15 a). Such lamination suggests extensive elastic recovery during 
decompression stage of the tableting cycle, which breaks bonding sites formed 
between particles during compression.70  To understand their difference on tableting 
performance, compressibility and compactibility profiles are also compared (Figure 
2.15b,c). At any given compaction pressure, the porosity of Lor tablets was always 
lower than those of the two new crystal forms, which were similar (Figure 2.15b).  





crystals, since the particle size and shape among them were similar (Figure 2.16). 
Interestingly, the apparent bonding strength, σ0 (tablet tensile strength at 0 porosity), 
of Lor-Oxa hydrate is the highest, followed by Lor and Lor-Oxa CAB (Figure 10c). 
Therefore, the higher tabletabillity of Lor is attributed by the larger bonding area not 
higher bonding strength according to the bonding area – bonding strength interplay 
model of tablet tensile strength.71  
When mixed with MCC, all three solid forms of Lor exhibited good tabletability, 
following the descending order of Lor > Lor-Oxa CAB > Lor-Oxa hydrate (Figure 
2.17).  All mixtures could form tablets with tensile strength of 2 MPa at pressures 
below 100 MPa.  Given the drug loading in the commercial Lor tablet products is 
around 2% because of the low dose of Lor (10 mg), no issue with tablet mechanical 
strength is expected for any of the three crystal forms with a suitable formulation. 2   
2.4 Conclusions 
We have discovered and characterized two new multi-component crystalline forms of 
Lor with Oxa.  Both crystal forms exhibit acceptable stability for drug development. 
Although both exhibit improved solubility and dissolution rate, Lor-Oxa CAB is much 
more soluble than Lor-Oxa hydrate. Therefore, Lor-Oxa CAB is the preferred crystal 
form for tablet formulation development although the Lor-Oxa hydrate is also suitable 
if desired.  However, the potential phase transition of Lor-Oxa CAB to Lor-Oxa 
hydrate during dissolution needs to be examined carefully to avoid unexpected 




















Table 2.2 Solubility at 25 °C (n = 3) and Intrinsic Dissolution Rate of Lor, Lor-Oxa 
CAB, Lor-Oxa hydrate at 37 °C (n = 3) in pH 6.8 phosphate buffer 
Material Lor Lor-Oxa CAB Lor-Oxa hydrate 
Solubility(mg·L−1) 0.7±0.0 -- 1.149±0.038 

























Figure 2.1. Chemical structures of (a) Loratadine (MW=382.88 g/mol) and (b) Oxalic 















































Figure 2.3. Experimental PXRD patterns of Lor, Oxa, Lor-Oxa CAB, Lor-Oxa hydrate, 










Figure 2.4 Crystal structure of Lor-Oxa CAB: (a) asymmetric unit; (b) oxalic acid 









Figure 2.5. Crystal structure of Lor-Oxa hydrate: (a) asymmetric unit;(b) Lor-water 












Figure 2.6. Effects of Oxa amount on phase change during slurry experiments. Lor to 










Figure 2.7 Thermal analysis of Lor-Oxa CAB and Lor-Oxa hydrate: (a) DSC, (b) TGA 
and HSM of (c) Lor-Oxa CAB and (d) Lor-Oxa hydrate. 
 
 








































































Figure 2.9. Moisture desorption and sorption isotherms of Lor-Oxa CAB (sorption 
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Figure 2.11. PXRD patterns of Lor-Oxa CAB and Lor-Oxa hydrate powders after 












Figure 2.12. (a) IDR of Lor, Lor-Oxa CAB, and Lor-Oxa hydrate, (b) IDR of Lor and 
Lor-Oxa hydrate, (c) PXRD pattern of Lor-Oxa CAB pellet after IDR study in 
comparision to those of Lor-Oxa CAB and Lor-Oxa hydrate, and (d) turbid bulk 










































Figure 2.14. (a) Tabletability, (b) compressibility, and (c) compatibility profiles of Lor, 













Figure 2.15. PLM images of (a) Lor, (b) Lor-Oxa CAB, and (c) Lor-Oxa hydrate for 










Figure 2.16. Tabletability profiles of Lor, Lor-Oxa CAB, and Lor-Oxa hydrate 
formulations. The formulation is comprised of 25% of one of the three Lor crystals 


























































3.1 Research Summary 
Two new multi-component crystalline forms of Lor with oxalic acid were discovered, 
i.e., , a 1:1 Loratadine - oxalic acid conjugate acid-base salt (Lor-Oxa CAB) and a 2:1 
Loratadine - oxalic acid monohydrate (Lor-Oxa hydrate). Crystal structures of both 
crystals were solved using single crystal X-ray diffraction, and the solid-state 
properties, tabletability, solubility, and intrinsic dissolution rate (IDR) were 
characterized. Both crystals show enhanced solubility and dissolution behavior over 
Lor, while Lor-Oxa CAB exhibited an IDR that is about 95 times higher than Lor.  
Both new crystal forms could be suitable for use in tablet formulation development, 
but Lor-Oxa CAB is preferred due to its higher solubility and better compression 
properties.     
3.2 Future Work 
Bulk precipitation phenomenon was observed on Lor-Oxa CAB during IDR study. 
Further exploration of the mechanism of this phenomenon may guide the development 
of a fast release and robust tablet formulation using Lor-Oxa CAB.  It is also a good 
model system to gain fundamental insight into the factors that control the precipitation 
during dissolution.  This is of value because soluble salts of the poorly soluble APIs 
tend to dissociate during the dissolution process in GI fluids.  Precipitation can occur 
either on the tablet surface or in the bulk media based on different mechanisms. During 
bulk precipitation, the poorly soluble drug precipitates out from the bulk medium, 
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